At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02367 GIANT BIOGENE
Market Closed 02-20 16:08:38
33.080
-1.160
-3.39%
High33.580Low32.700Vol1.03M
Open33.240D1 Closing34.240Amplitude2.57%
Mkt Cap35.43BTradable Cap35.43BTotal Shares1.07B
T/O33.80MT/O Rate0.10%Tradable Shares1.07B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Giant Biogene Shares Surge Over 8% in Hong Kong Trading Following Global First Approval for Injectable Collagen-Hyaluronic Acid Solution
Stock News  ·  02-05
Giant Biogene Shares Surge Over 8% in Hong Kong Trading Following Global First Approval for Injectable Collagen-Hyaluronic Acid Solution
HK Movers | New Consumption Stocks Gain With Giant Biogene up 6%, Pop Mart up 5%
Tiger Newspress  ·  02-05
HK Movers | New Consumption Stocks Gain With Giant Biogene up 6%, Pop Mart up 5%
Giant Biogene (02367) Releases January 2026 Monthly Return on Share Movements
Bulletin Express  ·  02-04
Giant Biogene (02367) Releases January 2026 Monthly Return on Share Movements
Giant Biogene Holding Insider Ups Holding During Year
Simply Wall St.  ·  01-27
Giant Biogene Holding Insider Ups Holding During Year
Jefferies Adjusts Giant Biogene's Price Target to HK$50 From HK$55, Keeps at Buy
MT Newswires Live  ·  01-26
Jefferies Adjusts Giant Biogene's Price Target to HK$50 From HK$55, Keeps at Buy
CICC Maintains "Outperform" Rating on GIANT BIOGENE (02367) as Second Recombinant Collagen Filler Receives Approval
Stock News  ·  01-16
CICC Maintains "Outperform" Rating on GIANT BIOGENE (02367) as Second Recombinant Collagen Filler Receives Approval
GIANT BIOGENE (02367) Surges Over 5% as Injectable Recombinant Collagen and Sodium Hyaluronate Complex Solution Gains Approval
Stock News  ·  01-16
GIANT BIOGENE (02367) Surges Over 5% as Injectable Recombinant Collagen and Sodium Hyaluronate Complex Solution Gains Approval
BRIEF-Giant Biogene's Unit Received NMPA Medical Device Registration Certificate For Recombinant Collagen, Sodium Hyaluronate Solution
Reuters  ·  01-15
BRIEF-Giant Biogene's Unit Received NMPA Medical Device Registration Certificate For Recombinant Collagen, Sodium Hyaluronate Solution
GIANT BIOGENE (02367) Wholly-Owned Subsidiary Receives NMPA Medical Device Registration Certificate for Recombinant Type I α1 Collagen and Sodium Hyaluronate Compound Solution
Stock News  ·  01-15
GIANT BIOGENE (02367) Wholly-Owned Subsidiary Receives NMPA Medical Device Registration Certificate for Recombinant Type I α1 Collagen and Sodium Hyaluronate Compound Solution
Giant Biogene - Unit Received Medical Device Registration Certificate From Nmpa China for Recombinant Collagen and Sodium Hyaluronate Solution
THOMSON REUTERS  ·  01-15
Giant Biogene - Unit Received Medical Device Registration Certificate From Nmpa China for Recombinant Collagen and Sodium Hyaluronate Solution
Shaanxi Giant Biotechnology Secures Approval for Innovative Skin Rejuvenation Product
Reuters  ·  01-15
Shaanxi Giant Biotechnology Secures Approval for Innovative Skin Rejuvenation Product
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$14.15 Million on January 14
Stock News  ·  01-14
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$14.15 Million on January 14
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$14.0029 Million on January 12
Stock News  ·  01-12
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$14.0029 Million on January 12
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$13.76 Million on January 9
Stock News  ·  01-09
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$13.76 Million on January 9
Hong Kong Stock Buyback Report | January 9
Stock News  ·  01-09
Hong Kong Stock Buyback Report | January 9
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$13.78 Million on January 7
Stock News  ·  01-07
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$13.78 Million on January 7
Zhito ng Hong Kong Stock 52-Week Highs and Lows Statistics | January 2nd
Stock News  ·  01-02
Zhito ng Hong Kong Stock 52-Week Highs and Lows Statistics | January 2nd
Hong Kong Stocks 52-Week Highs and Lows Statistics | December 31
Stock News  ·  2025-12-31
Hong Kong Stocks 52-Week Highs and Lows Statistics | December 31
HK Stock Movement | GIANT BIOGENE (02367) Falls Over 3% in Afternoon Trading; Institutions State Company's Investment Thesis Has Shifted from Growth to Strategic Adjustment, Lacking Clear Rebound Catalyst
Stock News  ·  2025-12-30
HK Stock Movement | GIANT BIOGENE (02367) Falls Over 3% in Afternoon Trading; Institutions State Company's Investment Thesis Has Shifted from Growth to Strategic Adjustment, Lacking Clear Rebound Catalyst
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$13.81 Million on December 29
Stock News  ·  2025-12-29
GIANT BIOGENE (02367) Repurchases 400,000 Shares for HK$13.81 Million on December 29

Introduction

Company Name.
GIANT BIOGENE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Giant Biogene Holding Co Ltd is an investment holding company primarily engaged in the research, development, manufacture and sale of bioactive material-based beauty and health products. The Company's main products include professional skin treatment products such as functional skincare products and medical dressings, as well as functional foods and others. The Company primarily conducts its businesses in domestic market.
Issue price:
--